Visceral fat area and subcutaneous fat area as measures of body composition in soft tissue sarcoma.
body mass index
obesity
soft tissue sarcoma
subcutaneous fat area
visceral fat area
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
received:
31
05
2024
accepted:
09
06
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
15
10
2024
Statut:
ppublish
Résumé
Soft tissue sarcomas (STS) are a heterogenous group of malignancies of mesenchymal origin. Given recent data linking obesity as well as the pattern of fat distribution with cancer outcomes, we sought to investigate the association of visceral fat area (VFA) and subcutaneous fat area (SFA) with oncologic outcomes in patients with STS undergoing surgery. We analyzed data from 88 patients with STS diagnosed from 2008 to 2022. Predictor variables included body mass index (BMI), VFA, and SFA. VFA and SFA were obtained from computed tomography of the abdomen and pelvis. Univariable and multivariable Cox regression analysis was used to analyze associations between predictor variables and overall survival and recurrence-free survival. Although BMI was closely correlated with VFA (r = 0.69, p < 0.0001) and SFA (r = 0.80, p < 0.0001), there was no significant association between high BMI, VFA or SFA, and worse oncologic outcomes. Although VFA and SFA are strongly correlated with BMI, we did not observe BMI nor imaging metrics of fat composition to be associated with worse oncologic outcomes. Further research is needed to elucidate any links between body fat content and metabolic or immune factors governing oncologic outcomes in STS.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Soft tissue sarcomas (STS) are a heterogenous group of malignancies of mesenchymal origin. Given recent data linking obesity as well as the pattern of fat distribution with cancer outcomes, we sought to investigate the association of visceral fat area (VFA) and subcutaneous fat area (SFA) with oncologic outcomes in patients with STS undergoing surgery.
METHODS
METHODS
We analyzed data from 88 patients with STS diagnosed from 2008 to 2022. Predictor variables included body mass index (BMI), VFA, and SFA. VFA and SFA were obtained from computed tomography of the abdomen and pelvis. Univariable and multivariable Cox regression analysis was used to analyze associations between predictor variables and overall survival and recurrence-free survival.
RESULTS
RESULTS
Although BMI was closely correlated with VFA (r = 0.69, p < 0.0001) and SFA (r = 0.80, p < 0.0001), there was no significant association between high BMI, VFA or SFA, and worse oncologic outcomes.
CONCLUSIONS
CONCLUSIONS
Although VFA and SFA are strongly correlated with BMI, we did not observe BMI nor imaging metrics of fat composition to be associated with worse oncologic outcomes. Further research is needed to elucidate any links between body fat content and metabolic or immune factors governing oncologic outcomes in STS.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
543-551Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Gamboa AC, Gronchi A, Cardona K. Soft‐tissue sarcoma in adults: an update on the current state of histiotype‐specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70:200‐229.
SEER. Cancer of soft tissue including heart—Cancer Stat Facts [Internet]; 2024. https://seer.cancer.gov/statfacts/html/soft.html
von Mehren M, Kane JM, Agulnik M, et al. Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:815‐833.
Lin X, Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Front Endocrinol. 2021;12:706978.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body‐mass index and incidence of cancer: a systematic review and meta‐analysis of prospective observational studies. Lancet. 2008;371:569‐578.
Park Y, Peterson LL, Colditz GA. The plausibility of obesity paradox in cancer—point. Cancer Res. 2018;78:1898‐1903.
Petrelli F, Cortellini A, Indini A, et al. Association of obesity with survival outcomes in patients with cancer: a systematic review and meta‐analysis. JAMA Network Open. 2021;4:e213520.
Tsekrekos A, Lovece A, Chrysikos D, et al. Impact of obesity on the outcomes after gastrectomy for gastric cancer: a meta‐analysis. Asian J Surg. 2022;45:15‐26.
Montgomery C, Harris J, Siegel E, et al. Obesity is associated with larger soft‐tissue sarcomas, more surgical complications, and more complex wound closures (obesity leads to larger soft‐tissue sarcomas). J Surg Oncol. 2018;118:184‐191.
Houdek MT, Griffin AM, Ferguson PC, Wunder JS. Morbid obesity increases the risk of postoperative wound complications, infection, and repeat surgical procedures following upper extremity limb salvage surgery for soft tissue sarcoma. Hand. 2019;14:114‐120.
Barnes ME, Elliott JA, McIntyre TV, Boyle EA, Gillis AE, Ridgway PF. Sarcopenia and obesity among patients with soft tissue sarcoma—association with clinicopathologic characteristics, complications and oncologic outcome: a systematic review and meta‐analysis. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2021;47:2237‐2247.
Houdek MT, Hevesi M, Griffin AM, Wunder JS, Ferguson PC. Morbid obesity is associated with an increased risk of wound complications and infection after lower extremity soft‐tissue sarcoma resection. J Am Acad Orthop Surg. 2019;27:807‐815.
Hendrickson NR, Mayo Z, Shamrock A, et al. Sarcopenia is associated with increased mortality but not complications following resection and reconstruction of sarcoma of the extremities. J Surg Oncol. 2020;121:1241‐1248.
Slump J, Ferguson PC, Wunder JS, et al. Patient, tumour and treatment factors affect complication rates in soft tissue sarcoma flap reconstruction in a synergistic manner. Eur J Surg Oncol (EJSO). 2017;43:1126‐1133.
Alamanda VK, Moore DC, Song Y, Schwartz HS, Holt GE. Obesity does not affect survival outcomes in extremity soft tissue sarcoma. Clin Orthopaed Related Res. 2014;472:2799‐2806.
Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obesity Rev. 2010;11:11‐18.
Katzmarzyk PT, Brown JC, Yang S, et al. Association of abdominal visceral adiposity and total fat mass with cancer incidence and mortality in White and Black adults. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2022;31:1532‐1538.
Graffy PM, Pickhardt PJ. Quantification of hepatic and visceral fat by CT and MR imaging: relevance to the obesity epidemic, metabolic syndrome and NAFLD. Br J Radiol. 2016;89:20151024.
Pickhardt PJ, Jee Y, O'Connor SD, del Rio AM. Visceral adiposity and hepatic steatosis at abdominal CT: association with the metabolic syndrome. Am J Roentgenol. 2012;198:1100‐1107.
Fan J‐G, Farrell GC. VAT fat is bad for the liver, SAT fat is not! J Gastroenterol Hepatol. 2008;23:829‐832.
Park BJ, Kim YJ, Kim DH, et al. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J Gastroenterol Hepatol. 2008;23:900‐907.
Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Rev. 2000;21:697‐738. https://academic.oup.com/edrv/article/21/6/697/2424212
Regitz‐Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clinical Res Cardiol. 2006;95:136‐147.
Koda M, Kawakami M, Murawaki Y, Senda M. The impact of visceral fat in nonalcoholic fatty liver disease: cross‐sectional and longitudinal studies. J Gastroenterol. 2007;42:897‐903.
Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments. Circulation. 2007;116:39‐48.
Himbert C, Delphan M, Scherer D, Bowers LW, Hursting S, Ulrich CM. Signals from the adipose microenvironment and the obesity–cancer link—a systematic review. Cancer Prev Res. 2017;10:494‐506.
Decazes P, Ammari S, Belkouchi Y, et al. Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy‐treated cancer. J Immunother Cancer. 2023;11:e007315.
He M, Chen Z‐F, Zhang L, et al. Associations of subcutaneous fat area and systemic immune‐inflammation index with survival in patients with advanced gastric cancer receiving dual PD‐1 and HER2 blockade. J Immunother Cancer. 2023;11:e007054.
Fujiwara N, Nakagawa H, Kudo Y, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015;63:131‐140.
Pei X, Xie Y, Liu Y, et al. Imaging‐based adipose biomarkers for predicting clinical outcomes of cancer patients treated with immune checkpoint inhibitors: a systematic review. Front Oncol. 2023;13:1198723.
TeraRecon. Intuitive and impactful imaging [Internet]. 2024. https://www.terarecon.com/
Grignol VP, Smith AD, Shlapak D, Zhang X, Del Campo SM, Carson WE. Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti‐angiogenic therapy. Surg Oncol. 2015;24:353‐358.
Cruz SM, Sholevar CJ, Judge SJ, et al. Intratumoral NKp46+ natural killer cells are spatially distanced from T and MHC‐I+ cells with prognostic implications in soft tissue sarcoma. Front Immunol. 2023;14:1230534.
MacNeill AJ, Miceli R, Strauss DC, et al. Post‐relapse outcomes after primary extended resection of retroperitoneal sarcoma: a report from the Trans‐Atlantic RPS Working Group. Cancer. 2017;123:1971‐1978.
Nasirishargh A, Grova M, Bateni CP, et al. Sarcopenia and frailty as predictors of surgical morbidity and oncologic outcomes in retroperitoneal sarcoma. J Surg Oncol. 2023;127:855‐861.
Staiano AE, Broyles ST, Gupta AK, Katzmarzyk PT. Ethnic and sex differences in visceral, subcutaneous, and total body fat in children and adolescents. Obes Silver Spring. 2013;21:1251‐1255.
Kim EH, Kim H‐K, Lee MJ, et al. Sex differences of visceral fat area and visceral‐to‐subcutaneous fat ratio for the risk of incident type 2 diabetes mellitus. Diabetes Metab J. 2022;46:486‐498.
Rothman KJ. BMI‐related errors in the measurement of obesity. Int J Obes. 2008;32:S56‐S59.
Weir CB, Jan A. BMI classification percentile and cut off points. StatPearls. StatPearls Publishing; 2024. http://www.ncbi.nlm.nih.gov/books/NBK541070/
Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022;15:321‐335.
Gonzalez MC, Pastore CA, Orlandi SP, Heymsfield SB. Obesity paradox in cancer: new insights provided by body composition. Am J Clin Nutr. 2014;99:999‐1005.
Wirtz TH, Loosen SH, Schulze‐Hagen M, et al. CT‐based determination of excessive visceral adipose tissue is associated with an impaired survival in critically ill patients. PLoS One. 2021;16:e0250321.
Rickles AS, Iannuzzi JC, Mironov O, et al. Visceral obesity and colorectal cancer: are we missing the boat with BMI? J Gastrointest Surg. 2013;17:133‐143.
Schlecht I, Fischer B, Behrens G, Leitzmann MF. Relations of visceral and abdominal subcutaneous adipose tissue, body mass index, and waist circumference to serum concentrations of parameters of chronic inflammation. Obes Facts. 2016;9:144‐157.
Camhi SM, Bray GA, Bouchard C, et al. The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. Obes Silver Spring Md. 2011;19:402‐408.
Wang Z, Aguilar EG, Luna JI, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD‐1 checkpoint blockade. Nature Med. 2019;25:141‐151.
Ringel AE, Drijvers JM, Baker GJ, et al. Obesity shapes metabolism in the tumor microenvironment to suppress anti‐tumor immunity. Cell. 2020;183:1848‐1866.
McQuade JL, Daniel CR, Hess KR, et al. Association of body‐mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19:310‐322.
Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260:416‐422.
Boyle EA, Elliott JA, McIntyre TV, et al. Body composition is associated with operative and oncologic outcomes in the management of retroperitoneal and trunk soft tissue sarcoma. The Am J Surg. 2022;223:729‐737.
Barnes ME, Elliott JA, McIntyre TV, Boyle EA, Gillis AE, Ridgway PF. Sarcopenia and obesity among patients with soft tissue sarcoma—association with clinicopathologic characteristics, complications and oncologic outcome: a systematic review and meta‐analysis. Eur J Surg Oncol. 2021;47:2237‐2247.
Derstine BA, Holcombe SA, Ross BE, Wang NC, Wang SC, Su GL. Healthy US population reference values for CT visceral fat measurements and the impact of IV contrast, HU range, and spinal levels. Sci Rep. 2022;12:2374.